BioLineRx Advances GLIX1 Glioblastoma Trial as Company Reports 2025 Financial Results
Key Insights
BioLineRx is on track to initiate a Phase 1/2a clinical trial of GLIX1 for glioblastoma (search) treatment by the end of March 2026, marking the first-in-human study of this novel DNA damage response (search) inhibitor.
The company received USPTO patent allowance for GLIX1 covering 90% of all cancers where cytidine deaminase (search) is not over-expressed, extending patent protection until 2040 with possible five-year extension.
BioLineRx reported $1.2 million in revenues for 2025 from APHEXDA royalties and maintains $20.9 million cash runway extending into the first half of 2027.
BioLineRx Ltd. announced it is on track to initiate a Phase 1/2a clinical trial of GLIX1 for glioblastoma (search) treatment by the end of March 2026, representing a significant milestone for the company's lead oncology asset. The Israeli biopharmaceutical company also reported its 2025 financial results, showing improved operational efficiency and extended cash runway.
GLIX1 Advances to First-in-Human Testing
The upcoming Phase 1/2a trial will mark the first clinical evaluation of GLIX1, a first-in-class oral small molecule that targets DNA damage response (search) mechanisms in cancer cells. According to CEO Philip Serlin, GLIX1 "is a unique molecule with a novel mechanism of action that targets the DNA repair mechanism in cancer cells and has demonstrated compelling efficacy in numerous pre-clinical models, excellent blood-brain-barrier penetration and a favorable safety profile in toxicology studies."
Three renowned academic centers will participate in the clinical trial: Northwestern University led by Dr. Roger Stupp and Dr. Ditte Primdahl, NYU Langone Health led by Dr. Alexandra M. Miller, and Moffitt Cancer Center led by Dr. Patrick Grogan.
The Phase 1 portion will recruit up to 30 patients with recurrent and progressive glioblastoma (search) and other high-grade gliomas. The primary objective is to establish a maximum tolerated dose and recommended dose based on safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy. Data from Phase 1 are anticipated in the first half of 2027.
The Phase 2a expansion will include various population cohorts, including newly diagnosed and recurrent glioblastoma (search) patients, as well as additional cancer types with or without standard of care treatments such as PARP inhibitors.
Patent Protection Strengthened
BioLineRx received Notice of Allowance from the U.S. Patent and Trademark Office for a key patent covering GLIX1 for cancers in which cytidine deaminase (search) is not over-expressed beyond a specific threshold, estimated to encompass 90% of all cancers. This patent preserves the company's ability to evaluate GLIX1 in other cancers beyond glioblastoma (search), including both hematological and solid tumor types, and extends patent protection until 2040 with a possible patent-term extension of up to five years.
Motixafortide Programs Show Progress
Enrollment has accelerated in the CheMo4METPANC Phase 2b clinical trial evaluating motixafortide in combination with the PD-1 (search) inhibitor cemiplimab and standard chemotherapy (gemcitabine and nab-paclitaxel) for metastatic pancreatic ductal adenocarcinoma (search). The trial, led by Columbia University and supported by both Regeneron and BioLineRx, continues to anticipate a prespecified interim/futility analysis when 40% of progression-free survival events are observed, expected to occur in 2026.
In sickle cell disease (search) applications, final results from a Phase 1 clinical trial evaluating motixafortide for CD34+ (search) hematopoietic stem cell mobilization for gene therapies were presented at the American Society of Hematology Annual Meeting in December. A second study sponsored by St. Jude Children's Research Hospital continues to enroll patients.
Financial Performance and Outlook
BioLineRx reported revenues of $1.2 million for 2025, reflecting royalties from Ayrmid's commercialization of APHEXDA in stem cell mobilization in the U.S. APHEXDA sales totaled $6.7 million for the full year 2025, generating $1.2 million in royalty revenue for the company.
Research and development expenses decreased to $8.1 million in 2025, down $1.1 million or 11.5% compared to 2024, primarily due to lower motixafortide expenses following the out-licensing of U.S. rights to Ayrmid and decreased headcount, offset by expenses related to GLIX1 project initiation.
The company eliminated sales and marketing expenses in 2025 following the shutdown of U.S. commercial operations in the fourth quarter of 2024. General and administrative expenses decreased by $3.2 million or 50.3% to $3.1 million, primarily due to the reversal of a provision for doubtful accounts and reduced headcount.
Net loss for 2025 was $2.0 million, a significant improvement from the $9.2 million loss in 2024. As of December 31, 2025, BioLineRx maintained cash, cash equivalents, and short-term bank deposits of $20.9 million, sufficient to fund operations into the first half of 2027.
Strategic Focus on High-Value Opportunities
The company continues conducting preclinical activities to support GLIX1 development in additional cancer indications and investigating potential synergistic effects with PARP inhibitors. Serlin emphasized that both GLIX1 and the pancreatic cancer program "represent opportunities to introduce much-needed new treatment options to patients suffering from very challenging tumor types, while creating sustained value for our company."